INZY Inozyme Pharma, Inc.

Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

$6.77
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/24/2020
Outstanding shares:  23,664,747
Average volume:  33,887
Market cap:   $176,065,718
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45790W108
ISIN:        US45790W1080
Sedol:      BMVLGY1
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.27
PS ratio:   0.00
Return on equity:   -38.89%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy